Communicating emerging risks of SGLT2 inhibitors-timeliness and transparency of medicine regulators
BMJ
.
2020 May 4:369:m1745.
doi: 10.1136/bmj.m1745.
PMID:
32366378
DOI:
10.1136/bmj.m1745
No abstract available
Publication types
Published Erratum